Genetic testing, ethical concerns, and the role of patent law

2000 ◽  
Vol 57 (5) ◽  
pp. 370-375 ◽  
Author(s):  
Timothy A Caulfield ◽  
E Richard Gold
2015 ◽  
Vol 8 (1) ◽  
pp. 47-76
Author(s):  
Joseph Straus

The progress of medicine is heavily dependent on the progress of science and technology, which in turn depend on costly and risky investment in research and development. In this contribution, based on some concrete examples, new scientific achievements are presented as basis of modern medicine and source of ethical concerns. Addressed are also the role of scientists in coping with safety in ethical concerns as regards hazards of new technologies, costs of R&D investment in drug development and the role of patents in this context. In some detail the legal situation existing at an international and European level as regards exclusions from patentability based on reasons of ethics and morals is presented. A critical appraisal of the case law of the Court of Justice of the European Union as regards patentability of embryonic stem cells is offered.


2021 ◽  
Vol 30 (3) ◽  
pp. 529-542
Author(s):  
Aisling McMahon

AbstractThis article focuses primarily on to what extent novel beings, and particularly, beings which display something akin to human consciousness or agency would be (or should be) patentable under current European patent law. Patents grant the patent holder a right to exclude others from using the patented invention for the period of patent grant (usually 20 years). This allows the patent holder to control how that invention can or cannot be used by others downstream, granting patent holders a governance like function over the patented technology for the duration of the patent. Accordingly, the potential for patentability of novel beings gives rise to a myriad of ethical issues including: to what extent is it appropriate for patent holders to retain and exercise patents over “novel beings”; how issues of “agency” displayed by any “novel beings” would fit within the current patent framework, if at all; and to what extent existing exclusions from patentability might exclude patents on “novel beings” or whether changes within patent law may be needed if patents in relation to “novel beings” are deemed ethically problematic. This article focuses on such issues, and in doing so, also sheds light on the role of ethical issues within the patenting of advanced biotechnologies more generally.


2020 ◽  
Vol 159 (2) ◽  
pp. e22-e23
Author(s):  
Danielle Collins Greenberg ◽  
Daniella Kamara ◽  
Zina Tatsugawa ◽  
Marlene Mendoza ◽  
Elizabeth Pineda ◽  
...  

2006 ◽  
Vol 38 (3) ◽  
pp. 219-224 ◽  
Author(s):  
Sivia Barnoy ◽  
Dorit Appel ◽  
Chava Peretz ◽  
Hana Meiraz ◽  
Mally Ehrenfeld

Heart Rhythm ◽  
2022 ◽  
Author(s):  
Valeria Novelli ◽  
Mirella Memmi ◽  
Alberto Malovini ◽  
Andrea Mazzanti ◽  
Nian Liu ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document